+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Late cardiac effects of anthracycline containing therapy for childhood acute lymphoblastic leukemia



Late cardiac effects of anthracycline containing therapy for childhood acute lymphoblastic leukemia



Pediatric Blood and Cancer 48(7): 663-667



At present about 80% of children with acute lymphoblastic leukemia (ALL) will be cured following treatment with multi-drug chemotherapy. A major concern for this growing number of survivors is the risk of late effects of treatment. The aim of this study was to determine whether signs of cardiomyopathy were present in patients treated in childhood with cumulative anthracycline doses of less than 300 mg/m(2). Evaluation of cardiac function in a cohort of 63 long-term survivors in first continuous remission following treatment of ALL with multi-drug chemotherapy including anthracyclines was performed using standard M-mode echocardiography and tissue doppler imaging (TDI). Associations between age at diagnosis, cumulative dose of anthracycline, sex, length of follow-up, and deviations from normal values in M-mode echocardiograms were evaluated using univariate and multivariate regression analysis. TDI data were compared to normal values using Wilcoxon matched-pairs signed-ranks test. By standard M-mode echocardiography the most significant findings were diastolic dilation of the left ventricle, thinner interventricular septum (IVS), decreased left ventricular mass (LVM) in females, follow-up dependent dilation of the left ventricle in systole and follow-up dependent decrease in ejection fraction (EF). TDI abnormalities included signs of early diastolic dysfunction and myocardial hypertrophy, and were also found in structures that appeared normal by M-mode echocardiography. This study adds to the growing evidence that even low to moderate doses of anthracyclines might lead to progressive cardiac dysfunction. It is important that children treated with anthracyclines receive life long follow-up for signs of cardiomyopathy.

(PDF emailed within 0-6 h: $19.90)

Accession: 013749160

Download citation: RISBibTeXText

PMID: 17405151

DOI: 10.1002/pbc.20313


Related references

Late cardiac damage of anthracycline therapy for acute lymphoblastic leukemia in childhood. Pediatric Hematology & Oncology 17(7): 527-540, October-November, 2000

Late cardiotoxicity after low dose of anthracycline therapy for acute lymphoblastic leukemia in childhood. Journal of Cancer Survivorship 6(1): 95-101, 2012

Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. New England Journal of Medicine 324(12): 808-815, 1991

Late cardiac effects of doxorubicin in childhood acute lymphoblastic leukemia. Journal of the American College of Cardiology 11(2 SUPPL A): 135A, 1988

Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. Journal of Clinical Oncology 16(2): 545-550, 1998

Cardiac failure 30 years after treatment containing anthracycline for childhood acute lymphoblastic leukemia. Journal of Pediatric Hematology/Oncology 34(5): 395-397, 2012

Anthracycline dose in childhood acute lymphoblastic leukemia: issues of early survival versus late cardiotoxicity. Journal of Clinical Oncology 15(1): 61-68, 1997

Late Effects of Therapy in Childhood Acute Lymphoblastic Leukemia Survivors. Turkish Journal of Haematology 2018, 2018

Early response to induction therapy and occult testicular leukemia otl at end therapy predict late relapse lr in childhood acute lymphoblastic leukemia all. Pediatric Research 21(4 PART 2): 302A, 1987

Acute and late toxicities of pirarubicin in the treatment of childhood acute lymphoblastic leukemia: results from a clinical trial by the Japan Association of Childhood Leukemia Study. International Journal of Clinical Oncology 22(2): 387-396, 2016

Persistent presence of common acute lymphoblastic leukemia antigen positive cells in regenerating bone marrow after cessation of maintenance therapy in acute lymphoblastic leukemia of childhood. European Paediatric Haematology & Oncology 2(4): 217-219, 1985

Anthracycline cross-resistance pattern in childhood relapsed acute lymphoblastic leukemia. Blood 82(10 SUPPL 1): 54A, 1993

Endocrinological and cardiological late effects among survivors of childhood acute lymphoblastic leukemia. Turkish Journal of Haematology 30(3): 290-299, 2014

Late intensification therapy with high dose methotrexate in standard risk acute lymphoblastic leukemia in childhood. Proceedings of the American Association for Cancer Research Annual Meeting 30: 266, 1989

Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. Journal of Clinical Oncology 23(12): 2629-2636, 2005